Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388063 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
A Phase 2 study, sponsored by Callisto Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00388063: Completed Phase 2 study, sponsored by Callisto Pharmaceuticals.
NCT00388063 is a Phase 2 study that has completed, run by Callisto Pharmaceuticals. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388063, a Phase 2 study, has completed, sponsored by Callisto Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).
Interventions
- DRUG Atiprimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388063
The ClinicalTrials.gov registry entry for NCT00388063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Callisto Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atiprimod is the first listed.
NCT00388063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388063 about?
NCT00388063 is a clinical study titled "Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma". This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide...
What is the current status of trial NCT00388063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2006-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00388063?
The interventions under investigation include: Atiprimod (DRUG).
Who is sponsoring clinical trial NCT00388063?
This trial is sponsored by Callisto Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.